A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma-Reference-Cited by-同舟云学术

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Published:2003-06-26 Issue:26 Volume:348 Page:2609-2617
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Richardson Paul G.,Barlogie Bart,Berenson James,Singhal Seema,Jagannath Sundar,Irwin David,Rajkumar S. Vincent,Srkalovic Gordan,Alsina Melissa,Alexanian Raymond,Siegel David,Orlowski Robert Z.,Kuter David,Limentani Steven A.,Lee Stephanie,Hideshima Teru,Esseltine Dixie-Lee,Kauffman Michael,Adams Julian,Schenkein David P.,Anderson Kenneth C.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa030288

Cited by 2307 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients;Journal of Stem Cell Therapy and Transplantation;2024-08-08

2. Bortezomib-induced hepatotoxicity in a patient with multiple myeloma: A case report;Medical Reports;2024-08

3. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

4. Gastrointestinal toxicities of proteasome inhibitor therapy;Journal of Cancer Research and Clinical Oncology;2024-07-05

5. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07